The synthetic pathway for glucosylsphingosine in cultured fibroblasts.
The synthesis of glucosylsphingosine (GlcSph), a glucosylceramide (GlcCer) analogue devoid of fatty acids, in cultured fibroblasts was studied by using conduritol beta epoxide (CBE), an inhibitor of beta-glucosidase, and 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), an inhibitor of glucosylceramide (GlcCer) synthase (glucosyltransferase). When CBE was added to the culture medium, the intracellular beta-glucosidase activity decreased, and both GlcCer and GlcSph accumulated in the cells. After the addition of PDMP, the concentration of GlcCer decreased, while the content of GlcSph increased. When CBE and PDMP were added together, the intracellular accumulation of GlcSph to decreased to less than when CBE alone was added. Based on these results, the synthetic pathway for GlcSph was thus considered to not only be through the glucosylation of sphingosine, but also through the deacylation of GlcCer. When GlcCer (d18:1, C12:0) was added to the culture medium, the intracellular accumulation of GlcSph (d18:1) was evident, and it was also more pronounced in the presence of CBE. In addition, when GlcCer (d18:0, C12:0) was used, apparent accumulation of GlcSph (d18:0) was also observed. In order to determine whether or not the deacylase of GlcCer is identical to acid ceramidase, a deacylase of ceramide, the same experiments were carried out using fibroblasts from two patients with Farber disease, in which acid ceramidase is genetically deficient. The accumulation of GlcSph in the Farber disease fibroblasts after the loading of GlcCer for 7 days was found to be one-fifth of the control level.(ABSTRACT TRUNCATED AT 250 WORDS)
Department of Neurology, Neurological Institute, Faculty of Medicine, Kyushu University, Fukuoka.
Y
Y
Yamaguchi
N
N
Sasagasako
I
I
Goto
T
T
Kobayashi
D000215:Acylation; D002478:Cells, Cultured; D002554:Cerebrosides / Q000096:biosynthesis*; D005347:Fibroblasts / Q000378:metabolism; D005963:Glucosylceramides / Q000037:antagonists & inhibitors / Q000378:metabolism*; D005964:Glucosyltransferases / Q000037:antagonists & inhibitors; D006031:Glycosylation; D006801:Humans; D007294:Inositol / Q000031:analogs & derivatives / Q000494:pharmacology; D009025:Morpholines / Q000494:pharmacology; D011609:Psychosine / Q000031:analogs & derivatives; D013110:Sphingosine / Q000378:metabolism*; D001617:beta-Glucosidase / Q000037:antagonists & inhibitors
D002554:Cerebrosides; D005963:Glucosylceramides; D009025:Morpholines; D011609:Psychosine; D007294:Inositol; C035742:sphingosyl beta-glucoside; C033110:RV 538; D005964:Glucosyltransferases; D001617:beta-Glucosidase; D013110:Sphingosine; C011423:conduritol epoxide